Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference
2024年1月3日 - 10:00PM
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the
development of a new class of medicines, today announced that Mei
Mei Hu, Chief Executive Officer of Vaxxinity, will present an
update on the Company and its pipeline at the 42nd Annual J.P.
Morgan Healthcare Conference on Thursday, January 11, 2024, at
10:30am PST.
About Vaxxinity
Vaxxinity, Inc. is a purpose-driven biotechnology company
committed to democratizing healthcare across the globe. The company
is pioneering a new class of medicines aimed at disrupting the
existing treatment paradigm for chronic disease, increasingly
dominated by monoclonal antibodies, which suffer from prohibitive
costs and cumbersome administration. The company’s proprietary
technology platform has enabled the innovation of novel synthetic
peptide immunotherapy candidates designed to bring the efficiency
of vaccines to the treatment of chronic diseases, including
Alzheimer’s disease, Parkinson’s disease, migraine, and
hypercholesterolemia. The technology is also implemented as part of
a COVID-19 vaccine program. Vaxxinity has optimized its pipeline to
achieve a potentially historic, global impact on human health.
For more information about Vaxxinity, Inc., visit
http://www.vaxxinity.com and follow us on social media
@vaxxinity.
Forward-looking Statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. The use of certain words, including "believe," "may,"
"continue," "advancing," "will" and similar expressions, are
intended to identify forward-looking statements. Forward-looking
statements include statements, other than statements of historical
fact, regarding, among other things: the plans for, or progress,
scope, initiation, duration, enrollment, results or timing for
availability of results of, development of any of Vaxxinity’s
product candidates or programs; the target indication(s) for
development or approval, the size, design, population, location,
conduct, cost, objective, enrollment, duration or endpoints of any
clinical trial, or the timing for initiation or completion of or
availability or reporting of results from any clinical trial; the
potential future regulatory authorization or approval and
commercialization of Vaxxinity’s product candidates; the potential
benefits or competitive position of any Vaxxinity product candidate
or program or the commercial opportunity in any target indication;
and Vaxxinity’s plans, expectations or future operations, financial
position, revenues, costs or expenses. These forward-looking
statements involve substantial risks and uncertainties, including
statements that are based on the current expectations and
assumptions of Vaxxinity’s management about the development of a
new class of immunotherapeutic vaccines and the innovation and
efficacy of Vaxxinity’s product candidates. Various important
factors could cause actual results or events to differ materially
from those that may be expressed or implied by our forward-looking
statements, including, but not limited to: whether UB-311, UB-312,
UB-313, VXX-401, UB-612 or any other current or future product
candidate of Vaxxinity will be approved or authorized by any
regulatory agency for the indications that Vaxxinity targets; any
potential negative impacts of the COVID-19 pandemic, including on
manufacturing, supply, conduct or initiation of clinical trials, or
other aspects of Vaxxinity’s business; Vaxxinity’s product
candidates may not be successful or clinical development may take
longer and be more costly than anticipated; product candidates that
appeared promising in earlier research and clinical trials may not
demonstrate safety or efficacy in larger-scale or later clinical
trials or in clinical trials for other indications; the timing for
initiation or completion of, or for availability of data from,
clinical trials for UB-311, UB-312, UB-313, VXX-401 or UB-612, and
the outcomes of such trials; Vaxxinity’s reliance on collaborative
partners and other third parties for development of its product
candidates; Vaxxinity’s ability to obtain coverage, pricing or
reimbursement for any approved products and acceptance from
patients and physicians for any approved indications; delays or
other challenges in the recruitment of patients for, or the conduct
of, Vaxxinity’s clinical trials; challenges associated with supply
and manufacturing activities; and Vaxxinity’s accounting policies.
These and other important factors to be considered in connection
with forward-looking statements are described in the "Risk Factors"
section of Vaxxinity’s Annual Report on Form 10-K filed with the
U.S. Securities and Exchange Commission on March 27, 2023. The
forward-looking statements are made as of this date and Vaxxinity
does not undertake any obligation to update any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by law.
Investor ContactMark
Joinnidesir@vaxxinity.com
Press ContactJon Yumedia@vaxxinity.com
Vaxxinity (NASDAQ:VAXX)
過去 株価チャート
から 4 2024 まで 5 2024
Vaxxinity (NASDAQ:VAXX)
過去 株価チャート
から 5 2023 まで 5 2024